LFG
VYNE icon

Larson Financial Group’s VYNE Therapeutics VYNE Stock Holding History

Larson Financial Group’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1 Buy
+2
New +$1 ﹤0.01% 3627

Other funds holding VYNE

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
TC
T3 Companies New York $76.8M AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Larson Financial Group's VYNE Position: Q1 2026 in Review

Larson Financial Group opened a new position in VYNE Therapeutics (VYNE) in Q1 2026: 2 shares worth $1. The stake represents ﹤0.01% of the portfolio and ranks #3627 among its holdings.

45 funds tracked by Wall St. Rank hold VYNE as of Q1 2026.

  • Larson Financial Group held 2 shares of VYNE Therapeutics worth $1 as of Q1 2026.
  • VYNE Therapeutics was a new Larson Financial Group position in Q1 2026.
  • VYNE Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #3627 holding.
  • 45 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.